- Home
- KZIA vs TNFA Comparison
KZIA vs TNFA Comparison
Compare KZIA & TNFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- TNFA
- Stock Information
- Founded
- KZIA 1994
- TNFA 2014
- Country
- KZIA Australia
- TNFA United States
- Employees
- KZIA N/A
- TNFA N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- TNFA
- Sector
- KZIA Health Care
- TNFA
- Exchange
- KZIA Nasdaq
- TNFA NYSE
- Market Cap
- KZIA 860.8K
- TNFA 760.1K
- IPO Year
- KZIA 1999
- TNFA N/A
- Fundamental
- Price
- KZIA $3.64
- TNFA $0.22
- Analyst Decision
- KZIA Strong Buy
- TNFA
- Analyst Count
- KZIA 2
- TNFA 0
- Target Price
- KZIA $57.50
- TNFA N/A
- AVG Volume (30 Days)
- KZIA 30.1K
- TNFA 2.7M
- Earning Date
- KZIA 05-02-2025
- TNFA 04-11-2025
- Dividend Yield
- KZIA N/A
- TNFA N/A
- EPS Growth
- KZIA N/A
- TNFA N/A
- EPS
- KZIA N/A
- TNFA N/A
- Revenue
- KZIA $1,655,324.00
- TNFA N/A
- Revenue This Year
- KZIA N/A
- TNFA N/A
- Revenue Next Year
- KZIA N/A
- TNFA N/A
- P/E Ratio
- KZIA N/A
- TNFA N/A
- Revenue Growth
- KZIA 248000.00
- TNFA N/A
- 52 Week Low
- KZIA $2.86
- TNFA $0.16
- 52 Week High
- KZIA $79.00
- TNFA $3.37
- Technical
- Relative Strength Index (RSI)
- KZIA 44.45
- TNFA 35.77
- Support Level
- KZIA $2.86
- TNFA $0.18
- Resistance Level
- KZIA $3.77
- TNFA $0.20
- Average True Range (ATR)
- KZIA 0.50
- TNFA 0.04
- MACD
- KZIA 0.05
- TNFA -0.00
- Stochastic Oscillator
- KZIA 60.00
- TNFA 27.88
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About TNFA TNF PHARMACEUTICALS INC EFFEC
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.